The FDA declined to approve one of biotech’s most closely watched cancer drugs

Image: MarketWatch
ad slot · in-content video 16:9
Coverage
Coverage
- The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
- Colorectal cancer is the deadliest cancer among people under age 50, and no one is quite sure why
- The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.